Clinical trials
Phase 2 Multiple Sclerosis trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 3 |
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 6 |
| 2011 | 4 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Terminated | 9 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sanofi | 7 |
| Biogen | 6 |
| GlaxoSmithKline | 3 |
| Actelion | 2 |
| Charite University, Berlin, Germany | 2 |
| GeNeuro SA | 2 |
| Hoffmann-La Roche | 2 |
| Merck KGaA, Darmstadt, Germany | 2 |
| Novartis Pharmaceuticals | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 44 |
| Multiple Sclerosis, Relapsing-Remitting | 12 |
| Recurrence | 4 |
| Multiple Sclerosis, Chronic Progressive | 2 |
| Muscle Spasticity | 2 |
| Optic Neuritis | 2 |
| Cardiotoxicity | 1 |
| Demyelinating Diseases | 1 |
| Diffuse Cerebral Sclerosis of Schilder | 1 |
| Neuromyelitis Optica | 1 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.